NCT07349615 A Study of SHR-1918 In Participants With Hypertriglyceridemia

Eligibility & Interventions

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

Phase 3 trials are large pivotal studies comparing the treatment to current standard of care or placebo. Your participation directly contributes to the evidence needed for regulatory approval.

This trial targets 360 participants in total. It began in 2026-04-01 with a primary completion date of 2027-11.

Brief Summary

The purpose of the study is to evaluate the efficacy and safety of SHR-1918 in patients with hypertriglyceridemia. The efficacy and safety of SHR-1918 will be evaluated after 24-weeks and 48-weeks treatment.

Eligibility Criteria

Inclusion Criteria: 1. Male and female ≥ 18 years old, who is able and willing to provide a written informed consent. 2. 1.7 ≤ TG ≤ 5.6 mmol/L. 3. LDL-C \< 3.4 mmol/L. 4. Male and female subjects of childbearing potential and their partners must have no plans to donate sperm or become pregnant during the entire study period and after the last dose, and agree to use contraceptive methods as specified in the protocol. Exclusion Criteria: 1. History of severe allergies/hypersensitivity reactions, or clinically significant allergies/hypersensitivity reactions as judged by the investigator, or history of allergies to drugs with similar chemical structures. 2. Received or are currently receiving treatment with monoclonal antibodies, siRNA-based drugs, or ASO-based drugs targeting the same target prior to screening. 3. Have a history of pancreatitis prior to screening or randomization. 4. Acute ischemic ASCVD events within 3 months prior to screening or randomization. 5. Heart failure with New York Heart Association (NYHA) Class III-IV prior to screening or randomization. 6. Malignant tumors within 5 years. 7. Received plasma exchange therapy within 2 months prior to screening, or plans to receive plasma exchange therapy during the study period, or has received LDL receptor gene therapy prior to screening. 8. Have a history of diseases that significantly affect blood lipid levels, such as nephrotic syndrome, severe liver diseases, Cushing's syndrome, or have severe arrhythmia prior to screening or randomization. 9. Poorly controlled type 2 diabetes mellitus or previously diagnosed type 1 diabetes mellitus; poorly controlled hypertension. 10. Have a history of major surgery within 3 months prior to screening, or plans to undergo major surgery during the study period.

Contact & Investigator

Frequently Asked Questions

Related Trials